TriangleNCT02186509 · OUTCOME
Number of Participants With Complete or Partial Response
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Up to 5 years
What was measured
95% confidence intervals will be computed. Response was defined by the Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Work Group (RANO)
Groups in this outcome
Alisertib, Fractionated Stereotactic Radiosurgery
CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery QD every weekday for 10 days and receive alisertib PO BID concurrently with radiation therapy for 10 days. MAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Hyperfractionated radiation therapy: Undergo hyperfractionated radiation therapy Stereotactic radiosurgery: Undergo stereotactic radiosurgery Alisertib: Given PO Quality-of-life assessment: Ancillary studies
| Group | Source count |
|---|---|
| Alisertib, Fractionated Stereotactic Radiosurgery | 17 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Alisertib, Fractionated Stereotactic Radiosurgery | 0 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 17
- units
- Participants
- description
- 95% confidence intervals will be computed. Response was defined by the Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Work Group (RANO)
- groups
- description
- CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery QD every weekday for 10 days and receive alisertib PO BID concurrently with radiation therapy for 10 days. MAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Hyperfractionated radiation therapy: Undergo hyperfractionated radiation therapy Stereotactic radiosurgery: Undergo stereotactic radiosurgery Alisertib: Given PO Quality-of-life assessment: Ancillary studies
- id
- OG000
- title
- Alisertib, Fractionated Stereotactic Radiosurgery
- param Type
- COUNT_OF_PARTICIPANTS
- reporting Status
- POSTED
- time Frame
- Up to 5 years
- title
- Number of Participants With Complete or Partial Response
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice